Nasus Pharma is a clinical-stage pharmaceutical company founded in Israel in 2019, developing intranasal powder-based drugs for emergency medical conditions. The company has no approved products and no product revenue. Nasus's core asset is NS002, an intranasal epinephrine powder spray designed as a needle-free alternative to the EpiPen auto-injector for treating anaphylaxis. The product targets the roughly 7 million U.S. patients prescribed epinephrine, addressing well-documented problems with EpiPen: needle fear, stability issues, high cost, and low patient compliance. Nasus's proprietary Nasax platform creates uniform spherical drug particles that disperse broadly across the nasal cavity, enabling faster absorption than liquid sprays. Phase 2 results showed NS002 reached a clinically meaningful plasma threshold in a median of 1.69 minutes vs. 3.42 minutes for EpiPen, with roughly 50% higher total absorption in the first 10 minutes. Nasus plans an IND submission in Q3 2026, a pivotal Phase 3 study in Q4 2026, and an NDA submission in the second half of 2027, using the FDA 505(b)(2) pathway. Nasus also developed NS001, an intranasal naloxone powder for opioid overdose reversal, but has paused that program and is seeking a partner. Earlier-stage pipeline candidates include intranasal formulations for nausea, metabolic, and cardiovascular indications. Nasus operates as a virtual company with no employees and outsources manufacturing to third-party facilities in Europe. If NS002 is approved, Nasus plans to commercialize through partnerships rather than building its own sales force, with royalties owed to device supplier Aptar France. Nasus carries an accumulated deficit of $18.5M and will need to raise additional capital to fund its Phase 3 study.